Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
Multidrug resistance (MDR), especially that associated with overexpression of MDR1 and its product, P-glycoprotein (Pgp), is thought to play a role in the outcome of therapy for some human tumors; however, a consensus conclusion has been difficult to reach, owing to the variable results published by different laboratories. Many factors appear to influence the detection of Pgp in clinical specimens, including its low and heterogeneous expression; conflicting definitions of detection end points; differences in methods of sample preparation, fixation, and analysis; use of immunological reagents with variable Pgp specificity and avidity and with different recognition epitopes; use of secondary reagents and chromogens; and differences in clinical end points. Also, mechanisms other than Pgp overexpression may contribute to clinical MDR. The combined effect of these factors is clearly important, especially among tumors with low expression of Pgp. Thus, a workshop was organized in Memphis, Tennessee, to promote the standardization of approaches to MDR1 and Pgp detection in clinical specimens. The 15 North American and European institutions that agreed to participate conducted three preworkshop trials with well-characterized MDR myeloma and carcinoma cell lines that expressed increasing amounts of Pgp. The intent was to establish standard materials and methods for a fourth trial, assays of Pgp and MDR1 in clinical specimens. The general conclusions emerging from these efforts led to a number of recommendations for future studies: (a) although detection of Pgp and MDR1 is at present likely to be more reliable in leukemias and lymphomas than in solid tumors, accurate measurement of low levels of Pgp expression under most conditions remains an elusive goal; (b) tissue-specific controls, antibody controls, and standardized MDR cell lines are essential for calibrating any detection method and for subsequent analyses of clinical samples; (c) use of two or more vendor-standardized anti-Pgp antibody reagents that recognize different epitopes improves the reliability of immunological detection of Pgp; (d) sample fixation and antigen preservation must be carefully controlled; (e) multiparameter analysis is useful in clinical assays of MDR1/Pgp expression; (f) immunostaining data are best reported as staining intensity and the percentage of positive cells; and (g) arbitrary minimal cutoff points for analysis compromise the reliability of conclusions. The recommendations made by workshop participants should enhance the quality of research on the role of Pgp in clinical MDR development and provide a paradigm for investigations of other drug resistance-associated proteins.
Beck
W T
WT
St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Grogan
T M
TM
Willman
C L
CL
Cordon-Cardo
C
C
Parham
D M
DM
Kuttesch
J F
JF
Andreeff
M
M
Bates
S E
SE
Berard
C W
CW
Boyett
J M
JM
Brophy
N A
NA
Broxterman
H J
HJ
Chan
H S
HS
Dalton
W S
WS
Dietel
M
M
Fojo
A T
AT
Gascoyne
R D
RD
Head
D
D
Houghton
P J
PJ
Srivastava
D K
DK
Lehnert
M
M
Leith
C P
CP
Paietta
E
E
Pavelic
Z P
ZP
Weinstein
R
R
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis* / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D005069:Evaluation Studies as Topic; D006801:Humans; D007150:Immunohistochemistry; D007624:KB Cells; D009369:Neoplasms / Q000737:chemistry* / Q000188:drug therapy*; D014407:Tumor Cells, Cultured
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1